ADvance II Study Testing Deep Brain Stimulation in Mild Alzheimer’s Started, Enrollment Ongoing

ADvance II Study Testing Deep Brain Stimulation in Mild Alzheimer’s Started, Enrollment Ongoing
The first patient enrolled in the ADvance II Study has been implanted with a deep brain stimulation (DBS) device to start treatment for mild Alzheimer's disease. The study will evaluate the safety and effectiveness of stimulating the fornix (DBS-f) — a major inflow and output pathway in the brain's memory circuit. The first participant was recruited by Anna Burke, MD, director of the Alzheimer's and Memory Disorders Division at Barrow Neurological Institute, and by Francisco Ponce, MD, director of the Barrow Center for Neuromodulation. The double-blind trial (NCT03622905) is currently recruiting up to 210 participants, ages 65 or older, across 14 sites in the U.S., Canada, and Germany. Eligible patients should be in good general health and on a stable dose of Aricept (donepezil, by Pfizer and Eisai), Razadyne (
Subscribe or to access all post and page content.